Ann: Presentation to Investors, page-16

BIT225 Opportunity Summary

BIT225 is a very important clinical asset for Biotron

• Previous positive clinical trial data have significantly de-risked the program
• Clear clinical development program designed to demonstrate to regulators and pharma how the drug may be
used to improve health outcomes in combination with ART

• SARS-CoV-2/COVID-19 program provides further value for BIT225 with results from the completed Phase 2
COVID-10 clinical trial expected shortly

• Results from three Phase 2 trials will be significant near-term milestones

• Positive data from these trials across two different disease indications will put the Company in a strong
position as it moves to partner the programs in 2024

• Pipeline of earlier stage, high value programs provide a solid base and potential future value for the Company

SARS-CoV-2/COVID-19 program provides further value for BIT225 with results from the completed Phase 2
COVID-10 clinical trial expected shortly

looks like a real winner to me Hang in there for a TH